Dessicated liposome technology improves vaccine stability
Mountain
Valley MD, Ontario, Canada
The results of the first study to evaluate the
stability of Trivalent Inactivated Poliovirus Vaccine (tIPV) formulated in
desiccated liposomes (QuIcksometm) has yielded promising results.
The technique involves laying down a film of desiccated liposomes containing
the vaccine in a vial. The vaccine is the reconstituted using Water for
Injection at the point of administration. Testing the stability of the vaccine at higher
ambient temperatures is important to comply with World Health Organisation
(WHO) Controlled Temperature Chain requirements.
Controlled Temperature Chain (CTC)
The WHO Controlled Temperature Chain allows
vaccines to be kept at temperatures outside the traditional cold chain of +2°C
to +8°C for a limited period of time under monitored and controlled conditions,
as appropriate to the stability of the antigen. A CTC typically involves a
single excursion of the vaccine into ambient temperatures not exceeding a
specified threshold temperature and for a duration of a specific number of
days, just prior to administration.
Controlled cold chain testing results
The
trivalent IPV stability evaluation was conducted to assess the preservation
application of MVMD’s Quicksome™ technology after five days exposure to 40°C.
Trivalent IPV comprises three serotypes of inactivated polioviruses. IPV
serotype two achieved 100% preservation
and stability; IPV serotypes one and three achieved 50% preservation and
stability. The 100% preservation and stability of IPV serotype two exceeds the
World Health Organization’s (WHO) guideline temperature requirements for all
three defined vaccine management categories including traditional cold chain
between +2°C and +8°C, Extended Controlled Temperature Conditions (ECTC) above
+8°C for a specified number of days to support vaccine distribution, and
Controlled Temperature Chain (CTC) where the vaccine must be able to tolerate
ambient temperatures of at least +40°C for a minimum of 3 days.
Previously MVMD has achieved 100% preservation of all three serotypes in a thin film
format up to 30°C.
Dennis Hancock (President &
CEO, Mountain Valley MD) said,
“IPV serotypes one and three will be the focus of
the next phase of evaluation the company will conduct by focusing on lowering
residual moisture content, achieving more robust liposomal protection, and
faster drying of the mixture within the vial.
Our objective is to achieve full CTC compliance at 40°C for tIPV polio
vaccines in a vial format that can be reconstituted at the point of
administration for injection, and we are immediately commencing this work with
the Food and Drug Administration (FDA) Polio Lab under our recently signed
collaborative research agreement.”
Cold chain
challenges and opportunities
Cold chain is a temperature-controlled supply chain
that prescribes necessary conditions during the transport, storage, and
handling of vaccines to preserve a temperature range between +2°C and +8°C from
the time the vaccine is produced until it is administered. Current estimates place cold chain biopharma
logistics spending for 2020 at USD $17.2 billion annually, with costs due to
failures in temperature-controlled logistics estimated at approximately USD $35
billion per year, and in most cases representing over half of a vaccine’s
cost. The WHO estimates that more than
50% of vaccines are wasted globally every year due to temperature control,
logistics and shipment-related issues.
The Quicksome™ technology holds out the possibility of reducing the complexity,
wastage and significant costs associated with cold chain distribution.